Blackrock Innovation And Growth Term Trust (BTX)

개요 뉴스 가격 이력 토론 예측

Relative Volume:

Blackrock Innovation And Growth Term Trust Stock (BTX) Company Profile

Blackrock Innovation And Growth Term Trust

Financial (4997)

2022-03-09T10:59:00.000Z

최신 SEC 제출 서류

BTX's Discussions on Twitter

BTX을(를) 다른 주식과 비교

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
BTX Brooklyn Immunotherapeutics Inc	7.66	10.67M	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	484.24	124.35B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	700.33	76.56B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	644.48	39.16B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	250.59	32.44B	2.25B	-278.16M	-42.59M	-2.17
BNTX Biontech Se Adr	120.01	28.77B	3.30B	-501.07M	1.03B	-2.1146

Blackrock Innovation And Growth Term Trust Stock (BTX) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2021-12-29	개시	Cantor Fitzgerald	Overweight
2021-10-06	개시	Maxim Group	Buy

Blackrock Innovation And Growth Term Trust 주식(BTX)의 최신 뉴스

Blackrock Innovation And Growth Term Trust (BTX) 재무 분석

Blackrock Innovation And Growth Term Trust (BTX)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.

Blackrock Innovation And Growth Term Trust (BTX)

Blackrock Innovation And Growth Term Trust Stock (BTX) Company Profile

BTX을(를) 다른 주식과 비교

Blackrock Innovation And Growth Term Trust Stock (BTX) Upgrades & Downgrades

Blackrock Innovation And Growth Term Trust 주식(BTX)의 최신 뉴스

Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated at StockNews.com - Defense World

Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by StockNews.com - Defense World

StockNews.com Initiates Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX) - Defense World

Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated by Analysts at StockNews.com - Defense World

Eterna Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com Australia

Eterna Therapeutics faces Nasdaq delisting over share price - Investing.com India

StockNews.com Begins Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX) - Defense World

Brooklyn ImmunoTherapeutics (NYSE:BTX) Earns Hold Rating from Analysts at StockNews.com - Defense World

BNY Mellon Ultra Short Income ETF (NYSEARCA:BKUI) Stock Price Up 0% – Should You Buy? - Defense World

Athersys (NASDAQ:ATHX) Research Coverage Started at StockNews.com - Defense World

StockNews.com Begins Coverage on Avangrid (NYSE:AGR) - Defense World

General Electric (NYSE:GE) Shares Bought by Creative Planning - Defense World

Week Ahead (Apr.12- Apr.16): PDUFA Dates, Data Readouts (RCUS, ATXI, MRTX, KDNY…) - RTTNews

‘Today you’re going to die’. Man ‘disrespected’ at family event kills cousin, MN cops say - Kansas City Star

15-Year-Old Shot Outside Brooklyn High School: Police - Patch

Teen Shot Outside Brooklyn High School - BK Reader

BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp Has $87.23 Million Holdings in Intuit Inc. (NASDAQ:INTU) - MarketBeat

Eterna Therapeutics faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com Canada

Eterna Therapeutics faces Nasdaq delisting over equity shortfall - Investing.com India

Itau Unibanco Holding S.A. Takes Position in Bristol-Myers Squibb (NYSE:BMY) - Defense World

Video NYPD releases body camera video of police shooting at Brooklyn Subway station - ABC News

Brooklyn Farebeater Who Cops Shot Pleads Not Guilty From Hospital Bed - Brooklyn, NY Patch

Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by Analysts at StockNews.com - Defense World

Brooklyn ImmunoTherapeutics (NYSE:BTX) Research Coverage Started at StockNews.com - MarketBeat

Eterna Therapeutics sets September 27 for annual meeting - Investing.com

Exclusive: RNA firm Eterna Therapeutics buys neighboring startup for $50M - The Business Journals

Eterna Therapeutics Reports Financial Results for Fourth Quarter and Full Year 2022 and Recent Business Highlights - GlobeNewswire

Kevin D’Amour, PhD, Joins Stemson Therapeutics as Chief Scientific Officer - Business Wire

ERNA Stock Price and Chart — NASDAQ:ERNA - TradingView

Eterna Therapeutics Completes Name Change, Acquires Option - GlobeNewswire

Brooklyn hails immunotherapy for achieving 'primary objective'—but fails the primary endpoint - Fierce Biotech

“Chemical and Biomolecular Strategies for STING Pathway Activation in Cancer Immunotherapy” published in Chemical Reviews, selected as VINSE Spotlight Publication - Vanderbilt University

SpyBiotech Appoints Mark Leuchtenberger as Chief Executive Officer - citybiz

iPSC-derived dopamine progenitor cell therapy in Parkinson’s disease - RegMedNet

Brooklyn ImmunoTherapeutics Announces $12 Million Private Placement - StockTitan

Brooklyn ImmunoTherapeutics Named to Nasdaq Biotechnology Index - StockTitan

Longeveron: A Meme Stock That Will Oscillate Before Dropping (NASDAQ:LGVN) - Seeking Alpha

New R&D Center Will Focus on Cell-based Therapies - Sickle Cell Disease News

7 Top-Rated Pharmaceutical Companies to Invest In for July - InvestorPlace

Swedish MPA Approves Atossa Therapeutics Inc (NASDAQ: ATOS) To Conduct Phase 2 Clinical Trial Of Oral Endoxifen To Reduce Mammographic Breast Density - BP Journal

10 Top Penny Stocks On Robinhood To Watch Right Now Before July 2021 - Penny Stocks

Brooklyn Immunotherapeutics Inc (NYSEAMERICAN: BTX) Incorporates R&D Center In Cambridge, Massachusetts To Develop mRNA-based Gene Editing/ Cellular Therapies - BP Journal

Brooklyn ImmunoTherapeutics Stock Rises After Novellus Therapeutics Buyout Deal - Benzinga

Brooklyn ImmunoTherapeutics CEO Howard J. Federoff Provides Roadmap for the Company’s Future During May 25, 2021 Shareholder Update Call - StockTitan

Brooklyn ImmunoTherapeutics Strengthens Investment in Licensed mRNA Technology Platform with $20M Financing - Business Wire

Michael Andreeff, M.D., Ph.D to Join the Scientific Advisory Board of Brooklyn ImmunoTherapeutics, Inc. - Business Wire

CDE China Grants IND Approval For Vicineum Of Sesen Bio Inc (NASDAQ:SESN) - BP Journal

Christopher Rohde, Ph.D. to Join Scientific Advisory Board of Brooklyn ImmunoTherapeutics - citybiz

Citius Pharmaceuticals Inc (NASDAQ:CTXR) Reports Strong Presence Of Clinical Trial Staff, Investigators, And Referring Physicians In A Webinar On Mino-Lok Phase 3 Clinical Trial - BP Journal

Brooklyn ImmunoTherapeutics: Time To Sell (NYSE:BTX) - Seeking Alpha

Blackrock Innovation And Growth Term Trust (BTX) 재무 분석

매출

순이익

현금흐름

주당 순 이익

BTX과 유사한 종목